Pfizer announced strong third-quarter profits, allowing it to raise its 2025 profit forecast. This improvement relies on major cost-cutting efforts, even as the company faces fierce competition and a high-stakes legal fight over the obesity startup Metsera.
Merck cuts 2025 revenue guidance and misses key drug sales targets in Q3, while preparing for Keytruda patent expiration and navigating tariff threats and China vaccine issues.
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.
IO Biotech won't submit its Cylembio cancer vaccine application after the FDA recommended against it due to trial results narrowly missing significance. IOBT will plan a new study and cut 50% of staff to save cash.
Evaxion secured a major licensing deal for its AI-discovered vaccine, EVX-B3, with Merck & Co. (MSD), potentially worth over $600 million and validating Evaxion's groundbreaking AI platform.
